Kornimate/medical-research-clean huggingface dataset:
virus surveillance in pediatric solid organ transplant recipients

Conditions: Viral Infections

Summary: viral infections are an important complication of transplantation. immunosuppressive therapy interferes with t cell immunity resulting in a high incidence of viral infection. newer agents, such as mycophenolate mofetil (mmf) and sirolimus, have been associated with an increased risk of herpes virus infection. the introduction of these more potent immunosuppressive agents over the past decade correlates with an increase in the rate of hospitalizations of transplant patients with infections. this prospective study will determine the role of sub-clinical herpes virus infections in the development of complications such as chronic allograft nephropathy (can) and post transplant lymphoproliferative disease (ptld). by focusing on treatable herpes virus infections, these studies have the potential to identify therapeutic strategies that can be used to diminish the burden of graft loss from can, significantly improving renal allograft survival and quality of life in transplant patients. future specific interventions to test the hypothesis of a direct causal relationship between sub-clinical herpes virus infection and can may include the use of anti-viral therapy in response to sub-clinical infection of the renal allograft and/or peripheral blood.


Eligibility criteria:
inclusion criteria: * age from birth to 21 years * all solid organ transplant recipients receiving their care at seattle children's hospital * signed consent, and when age appropriate, signed assent exclusion criteria: * lack of consent

Keywords: organ transplants
hpa antibodies and the distribution of antigen and antibodies

Conditions: Blood Disease; Platelet Refractoriness; Antibody-mediated Rejection

Summary: by detecting platelet antibodies of participants and then further to identify their genotype and analyzing laboratory examination, the investigators will obtain positive frequency of hpa antibodies, the distribution of hpa antigen and antibodies, effect of matching platelet transfusion, all of which in favor of draw a conclusion that it is very important to carry out hpa antibody detection and matching transfusion in early phase.

1. the investigators will detect platelet antibodies of participants who are according with the inclusive criteria. 2. for participants with platelet antibodies, the investigators should screen out cases owning hpa antibodies and further to identify their genotype. 3. platelet infusion of same type will be applied to half of participants with hpa antibodies as experimental group, and the another half of participants with hematopathy will be infused ordinary platelets as control. the investigators will estimate the effect of matching transfusion through laboratory examination such as platelet count 1 hour and 24 hours after transfusion and clinical feature comparing to control group. 4. finally, the investigators will obtain several conclusions includes positive frequency of hpa antibodies, the distribution of hpa antigen and antibodies, effect of matching platelet transfusion by analyzing a bunch of relevant information. so, strong evidence will be provide to decide if it is very important to carry out hpa antibody detection and matching transfusion in early phase.

Eligibility criteria:
inclusion criteria: 1. blood disease patients with voluntary participation in creating records, no gender limitation, 0-99 years of age, first diagnosed or be hospitalized in our hospital with platelet transfusion more than once. 2. patients transfers from other hospitals which can be confirm the time (\>1) of platelet transfusion. 3. patient be cured, discharged or dead with the time of platelet transfusion is between 1 to 10 should be included. 4. patient with hpa antibodies at admission could be considered to be included into same type transfusion group. - exclusion criteria: 1. patients informed but refuse to participate in; 2. patients with hpa antibodies quitting therapy or breaking off cooperation during research; 3. patients with many referrals and the time of platelet transfusion can not be confirmed; 4. patient without platelet transfusion; 5. patient with termination of treatment whatever active or passive. -

Keywords: hpa blood disease
phase ii/iii trial of cpt-11/5-fu/l-lv versus cpt-11/ts-1 as second line chemotherapy of unresectable colorectal cancer

Conditions: Colorectal Cancer

Summary: this study is designed as phase ii/iii. phase ii is aimed to evaluate safety and efficacy of iris, and feasibility of folfiri. phase iii is aimed to verify inferiority of the progression free survival of iris in comparison with folfiri.


Eligibility criteria:
inclusion criteria: * histologically confirmed colorectal cancer * locally advanced and/or metastatic colorectal cancer * have prior chemotherapy as first line treatment * no prior irinotecan administration * able to take oral medication * age 20 to 75 * performance status 0 or 1 (ecog) * wbc 3,000-12,000 / mm\^3 * platelet ≥100,000 / mm\^3 * ast and alt ≤ 100 iu/l * creatinine ≤ 1.2 mg/dl * bilirubin ≤ 1.5 mg/dl exclusion criteria: * prior radio therapy for colorectal cancer * other malignancies in the past 5 years * serious illness or medical condition

Keywords: colorectal cancer
adaptation of dialectical behavior therapy skills-groups for individuals with suicidal ideation and depression

Conditions: Suicidal Ideation; Major Depressive Disorder

Summary: harley and colleagues demonstrated that adding dialectical behavior therapy (dbt) skills-groups and therapist consultation to treatment as usual successfully reduced symptoms of depression. the present study will expand upon these findings. second, dbt is not known for reducing suicidal ideation (si), a major risk factor for suicide . the present study will tailor the aforementioned skills-groups to specifically target suicidal thoughts and behaviors through cognitive behavior therapy (cbt) strategies aimed at increasing problem-solving deficits, hopelessness, and negativistic thinking. third, the present study will extend this dbt-based approach to a novel population. fourth, the present study is the first dbt intervention to employ state-of-the-art multi-method measurement (including objective assessment) of suicidal thoughts and behaviors. the investigators hypothesize that participants in the dbt skills (dbt-s) group will show improvements in level of suicidality as measured by decreased scores on the beck scale for suicide ideation as compared with participants in the wait list-treatment as usual (wl-tau) group.


Eligibility criteria:
inclusion criteria: 1. participants will be at least 18 years of age. 2. participants will meet criteria for major depressive disorder (mdd) on the structured clinical interviews for axis i dsm-iv disorders 3. participants must report current suicidal ideation on the self-injurious thoughts and behaviors interview 4. participants must have an outpatient psychiatric provider who they see "regularly" (i.e., at least every other week for therapy, case management, or medication management). 5. english language proficiency. exclusion criteria: 1. dsm-iv diagnosis of bipolar disorder, schizophrenia, psychotic disorder nos, or personality disorders. 2. active current substance dependence. 3. severe or unstable medical conditions that would prohibit regular group attendance or participation. 4. other group therapy. 5. significant dementia or cognitive impairment that would interfere with the learning of dbt skills.
nebido in symptomatic late onset hypogonadism (sloh)

Conditions: Hypogonadism

Summary: the design of the study is a standard double-blind design, which is needed in this study to allow for unbiased evaluation of efficacy and safety. the effect of the additional impact of testosterone replacement therapy in hypogonadal men on muscle strength and quality of life in comparison to physical exercise alone will be assessed. treatment duration will be 54 weeks, to monitor the increase as well as the "steady state" of the parameters assessed.


Eligibility criteria:
inclusion criteria: * men aged 60 years and older (\>60yrs), untrained * symptomatic hypogonadism as defined by a) and b) * a) total testosterone below 12 nmol/l (measurement 7.00-11.00 a.m.) * b)total aging males' symptom score above 36 * willing to avoid significant change in the pattern of physical exercise and lifestyle for the duration of the study * residence in cologne area exclusion criteria: * previous assignment to treatment during this study * use of androgen therapy or anabolic steroids respectively 12 months of entry into the study (i.e. screening visit/visit 1) * current participation in an exercise program or within the last 6 months * suspicion or known history of prostate or breast cancer or other hormone dependent neoplasia * abnormal finding on digital rectal examination (dre) * prostate specific antigen (psa) level \>4 ng/ml * history of clinically significant post void residual urine (\> 150 ml) * suspicion or known history of liver tumor * hypersensitivity to the active substances or any of the excipients of nebido e.g. benzyl-benzoate and castor oil * blood coagulation irregularities presenting an increased risk of bleeding after intramuscular injections including vitamin-k-antagonists or other strong anticoagulants * 32 additional exclusion criteria

Keywords: testosterone undecanoate hypogonadism
modified folfirinox for gemcitabine refractory pancreatic cancer: a phase ii multicenter trial

Conditions: Pancreatic Ductal Adenocarcinoma

Summary: pancreatic ductal adenocarcinoma is the fourth cause of death in the western world. surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. since the approval of gemcitabine as a standard treatment for advanced pancreatic patients, no drug or combination of drugs has significantly improved the prognosis. recently, as compared with gemcitabine, folfirinox was associated with a survival advantage (11.1 vs 6.8 months), but had increased toxicity. in some retrospective studies, modified folfirinox regimen (60/120 mg/m2 of oxaliplatin and irinotecan) has an improved safety profile in digestive malignancies. the purpose of this phase ii multicenter study was to investigate the efficacy and safety in patients with pancreatic cancer who progressed in gemcitabine-based first line chemotherapy.


Eligibility criteria:
inclusion criteria: * pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally advanced stage) * refractory or progress to gemcitabine based 1st line chemotherapy * older than 19 years old and younger than 75 years old * life expectancy\> 3 months * ecog performance status ≤2 * only patients with measurable lesions in imaging study * adequete bm function (wbc ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl) * adequete liver function (total bilirubin \< 1.5 x the upper limits of normal (uln), ast and alt \<3 x unl, and alkaline phosphatases \< 3 x uln or \< 5 x uln in case of liver involvement) * adequete renal function (serum creatinine \< 1.5 mg/dl) * adequete cardiopulmonary function exclusion criteria: * pathologically confirmed another type of pancreatic cancer (except ductal adenocarcinoma) * metastatic adenocarcinoma of originating at other organs * evidence with cns metastasis * active infection * uncontrolled serious medical or psychiatric illness which can induce toxicity ro complication of treatment, such as inability to swallow, lacking physical integrity of the gastrointestinal tract, malabsorption syndrome, or active ulceration at upper gastrointestinal tract. * coexisting of other malignancies within 5 years, except squamous cell carcinoma and basal cell carcinoma of the skin * participation in any other investigational drug study within 1 month * no signed informed consent
ultrasound-assisted shamrock method for lumbar plexus nerve block in elderly trauma patients, revisited.

Conditions: Postoperative Pain

Summary: a revised ultrasound-guided approach to the lumbar plexus is investigated as for efficacy and safety in elderly trauma patients undergoing operations of the lower extremeties.

a modified ultrasound-guided shamrock approach combined to nerve stimulation of the lumbar plexus is going to be investigated, in elderly trauma patients undergoing procedures of the lower extremities. the technique is going to be assessed as for its safety and its accuracy in localization of the plexus, by multiple measurements of the imaging time and needling time, in addition, efficacy and complications will be recorded and assessed during the immediate postoperative period.

Eligibility criteria:
inclusion criteria: * patients undergoing orthopedic trauma operations of the lower extremeties * age \>70 years old exclusion criteria: * preexisting neuropathy of lumbar plexus * coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up ie platelets ≤ 100, international normalized ratio ≥ 1.4 or prothrombin time ≥ 50) * allergy to local anaesthetics * prior surgery at the lumbar region
physical characteristics of retrieved massive allografts

Conditions: Bone Cancer

Summary: this purpose of this study is to measure the strength of tissue allografts that have been in the body various lengths of time.

allograft bone is the primary source of graft material for large skeletal defects resulting from trauma, disease, oncological resection, or reconstruction of failed total joint arthroplasties. the physical characteristics of such grafts after various intervals of remodeling and incorporation in vivo have never been studied. the purpose of this study is to obtain tissue from allografts retrieved at autopsy, at amputation for oncological complications and from patients undergoing revision procedures for failed allograft transplantation. we will evaluate the mechanical properties, histomorphometric indices and presence of microfractures. our hypotheses are: * histomorphometric parameters of porosity and microfracture density will predict allograft strength, * microfracture density will be correlated with time in vivo and allograft strength, * the rate of host-allograft nonunion and fracture will correlate with radiation therapy and chemotherapy. the retrieved tissue will be processed using standard undecalcified histology and quantitatively assessed for degree of incorporation, allograft porosity, and microfracture density. the biomechanical characteristics of the bulk allograft and allograft-host junction will be quantified and compared to allograft bone prior to transplantation.

Eligibility criteria:
inclusion criteria: * failed allograft bone * removal of allograft due to oncological complications * amputation due to oncological complications exclusion criteria: * none
myopia control with three lever irradiance of pbm therapy in children and adults

Conditions: Myopia; Amblyopia; Refractive Error - Myopia Axial; Ametropia

Summary: photobiomodulation therapy, that is, low-level red-light technology provides a new and innovative myopia control approach. this strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. the efficacy of the low-level red-light technology has been proven in a chinese populationb for the recent 3 years with evidence based papers and amazing results. however, there's not yet evidence to demonstrate the relationship between the dose response effect of photobiomodulation therapy on myopia control at the different age lever.

previous trial has demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment at the irridiance of 2.3mw（2.0\~2.5mw) controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. retrospective analyze other irriadance of 1.2mw, 0.6mw and 0.37mw culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.

Eligibility criteria:
inclusion criteria: * myopia or near myopia with younger age * without other intervention of myopia control, including atropine, misight contact lens, special design lens to control myopia, orthokeratology and other red light devices. * follow-up at least once * with baseline data of ocular parameters before the follow-up exclusion criteria: * photophobia * allergy to red light * severe ocular progressing diseases or systemic diseases * the data is unacceptable with reasonable explanations

Keywords: myopia pbm therapy lllt
correlation analysis of pod and pncd in elderly patients with gastrointestinal neoplasms

Conditions: Postoperative Delirium; Postoperative Neurocognitive Disorder; Gastrointestinal Surgery

Summary: this is a prospective cohort study to explore the differences of serum indicators between elderly gastrointestinal neoplasms patients with postoperative delirium (pod) who either develop or do not develop long-term postoperative neurocognitive disorders (pncd).

the purpose of this study is to explore the differences of serum indicators between elderly gastrointestinal neoplasms patients with postoperative delirium (pod) who either develop or do not develop long-term postoperative neurocognitive disorders (pncd). elderly gastrointestinal neoplasms patients aged 65 and above, undergoing surgical operations at xuanwu hospital, capital medical university, were selected. the serum indicators of all patients were measured before surgery, and neurocognitive function of all patients was assessed using the montreal cognitive assessment (moca) within 1 week before surgery. general patient data such as sex, age, comorbidities, bmi, asa classification, and moca scores were collected. under routine anesthetic management of the department of anesthesiology and surgical operations at xuanwu hospital, endotracheal intubation general anesthesia was performed. intraoperative monitoring included heart rate, blood pressure, pulse oximetry, and body temperature, with surgery and anesthesia times, and fluid balance recorded. the serum indicators of all patients were measured after surgery. within 7 days post-surgery, delirium assessment was conducted using the confusion assessment method (cam), classifying patients into pod and non-pod groups. for the patients in the pod group, neurocognitive function was assessed at a period of time after surgery to determine the presence of pncd, further dividing the pod group into pncd and non-pncd subgroups. the correlation between pod and pncd was explored by comparing the changes of serum indicators before and after surgery in the pncd and non-pncd subgroups.

Eligibility criteria:
inclusion criteria: * patients ≥65 years of age who have undergone surgical anesthesia of gastrointestinal neoplasms; sign informed consent. exclusion criteria: * inability to complete cognitive function assessment; illiteracy, hearing impairment or visual impairment; he has a history of epilepsy, depression, schizophrenia, alzheimer's disease and other psychiatric and neurological diseases.

Keywords: postoperative delirium postoperative neurocognitive disorder serum indicators gastrointestinal neoplasms surgery
patient-assisted compression - impact on image quality and workflow

Conditions: Breast Cancer

Summary: this study is being conducted to compare the image quality of breast images obtained using standard (technologist-controlled \[tc\]) compression and patient-assisted (pa) compression and to evaluate the impact of pa compression on clinical workflow.

patient-assisted (pa) compression allows the patient to participate in controlling the amount of compression force during mammography and is a personalized approach that has demonstrated successful reduction in discomfort experienced during mammography. ge healthcare's senographe pristina, an innovative mammography platform that provides both two-dimensional (2d) and three-dimensional (3d) imaging capabilities, offers both standard and pa compression modes. this study is being conducted to compare the image quality of breast images obtained using tc compression and pa compression, and to evaluate the impact of pa compression on clinical workflow. the study population will consist of adult asymptomatic women presenting for screening 2d mammography.

Eligibility criteria:
inclusion criteria: * are women aged 40 years or older; * are asymptomatic and scheduled for ffdm screening mammography; * have left and right breasts; * have breast sizes compatible with the dimensions of a 24 x 31 cm image detector, without anatomical cut-off; * are documented as non-pregnant based on the investigator's medical judgment and in consideration of local clinical practice standards for evidence of non-pregnancy; * are able and willing to comply with study procedures; and * are able and willing to provide written informed consent to participate. exclusion criteria: * have been previously included in this study or are participating in another study expected to interfere with study procedures or outcomes; * have undergone diagnostic or surgical intervention(s) or procedure(s) on either breast, including breast biopsy, lumpectomy, or reconstruction, within five (5) years (≤ 5 years) of the study exam date; * are currently undergoing radiotherapy or chemotherapy, or have a history of prior radiotherapy treatment on either breast; * are currently lactating; or * have breast implants.